Point72 Asset Management
BOLD

Point72 Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Point72 Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-241,100
Closed -$6.77M – 1378
2019
Q3 		$6.77M Buy
241,100
+17,483
+8% +$597K 0.04% 411
2019
Q2 		$8.47M Sell
223,617
-49,983
-18% -$1.92M 0.04% 412
2019
Q1 		$10.7M Sell
273,600
-188,380
-41% -$5.4M 0.05% 379
2018
Q4 		$9.85M Buy
+461,980
New +$11.9M 0.05% 417
2017
Q3 		– Sell
-320,393
Closed -$6.13M – 1131
2017
Q2 		$6.13M Buy
+320,393
New +$5.12M 0.03% 479

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Point72 Asset Management's BOLD Position: Q4 2019 in Review

Point72 Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 241,100 shares — an estimated $6.77M sold.

Point72 Asset Management first reported a position in BOLD in Q2 2017 and held it in 5 quarters. The position peaked at $10.7M in Q1 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Point72 Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Point72 Asset Management sold 241,100 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $6.77M.
  • Point72 Asset Management first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 5 quarters.
  • Point72 Asset Management's Audentes Therapeutics, Inc position peaked at $10.7M in Q1 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.